fluphenazine has been researched along with lopinavir in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL | 1 |
| Kim, JY; Lee, BM; Park, YJ; Yoon, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 review(s) available for fluphenazine and lopinavir
| Article | Year |
|---|---|
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization | 2021 |
2 other study(ies) available for fluphenazine and lopinavir
| Article | Year |
|---|---|
Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.
Topics: Antimitotic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fluphenazine; Furans; HIV Protease Inhibitors; Humans; Ketones; Lopinavir; Mouth Neoplasms; Nelfinavir; Ritonavir; Vincristine | 2019 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |